These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 38573870

  • 1. Novel NF-κB Inhibitor-Conjugated Pt(IV) Prodrug to Enable Cancer Therapy through ROS/ER Stress and Mitochondrial Dysfunction and Overcome Multidrug Resistance.
    Wang M, Li G, Jiang G, Cai J, Liu Z, Huang R, Huang X, Wang H.
    J Med Chem; 2024 Apr 25; 67(8):6218-6237. PubMed ID: 38573870
    [Abstract] [Full Text] [Related]

  • 2. Glycyrrhetinic Acid as a Hepatocyte Targeting Ligand-Functionalized Platinum(IV) Complexes for Hepatocellular Carcinoma Therapy and Overcoming Multidrug Resistance.
    Huang X, Li G, Li H, Zhong W, Jiang G, Cai J, Xiong Q, Wu C, Su K, Huang R, Xu S, Liu Z, Wang M, Wang H.
    J Med Chem; 2024 May 23; 67(10):8020-8042. PubMed ID: 38727048
    [Abstract] [Full Text] [Related]

  • 3. Pt(IV) prodrugs containing microtubule inhibitors displayed potent antitumor activity and ability to overcome cisplatin resistance.
    Li L, Huang X, Huang R, Gou S, Wang Z, Wang H.
    Eur J Med Chem; 2018 Aug 05; 156():666-679. PubMed ID: 30031977
    [Abstract] [Full Text] [Related]

  • 4. Reversal of cisplatin resistance in human gastric cancer cells by a wogonin-conjugated Pt(IV) prodrug via attenuating Casein Kinase 2-mediated Nuclear Factor-κB pathways.
    Chen F, Qin X, Xu G, Gou S, Jin X.
    Biochem Pharmacol; 2017 Jul 01; 135():50-68. PubMed ID: 28288821
    [Abstract] [Full Text] [Related]

  • 5. Dual-targeting tumor cells hybrids derived from Pt(IV) species and NF-κB inhibitors enables cancer therapy through mitochondrial dysfunction and ER stress and overcomes cisplatin resistance.
    Wang M, Li G, Jiang G, Cai J, Zhong W, Huang R, Liu Z, Huang X, Wang H.
    Eur J Med Chem; 2024 Feb 15; 266():116095. PubMed ID: 38215589
    [Abstract] [Full Text] [Related]

  • 6. Dual-targeting antitumor conjugates derived from platinum(IV) prodrugs and microtubule inhibitor CA-4 significantly exhibited potent ability to overcome cisplatin resistance.
    Huang X, Wang M, Wang C, Hu W, You Q, Yang Y, Yu C, Liao Z, Gou S, Wang H.
    Bioorg Chem; 2019 Nov 15; 92():103236. PubMed ID: 31494328
    [Abstract] [Full Text] [Related]

  • 7. Targeting RAS-RAF pathway significantly improves antitumor activity of Rigosertib-derived platinum(IV) complexes and overcomes cisplatin resistance.
    Liu Z, Wang M, Wang H, Fang L, Gou S.
    Eur J Med Chem; 2020 May 15; 194():112269. PubMed ID: 32248002
    [Abstract] [Full Text] [Related]

  • 8. Complexes of oxoplatin with rhein and ferulic acid ligands as platinum(iv) prodrugs with high anti-tumor activity.
    Tan MX, Wang ZF, Qin QP, Zou BQ, Liang H.
    Dalton Trans; 2020 Feb 07; 49(5):1613-1619. PubMed ID: 31942585
    [Abstract] [Full Text] [Related]

  • 9. A cisplatin-based platinum(IV) prodrug containing a glutathione s-transferase inhibitor to reverse cisplatin-resistance in non-small cell lung cancer.
    Chen H, Wang X, Gou S.
    J Inorg Biochem; 2019 Apr 07; 193():133-142. PubMed ID: 30731264
    [Abstract] [Full Text] [Related]

  • 10. Precisely Assembled Nanoparticles against Cisplatin Resistance via Cancer-Specific Targeting of Mitochondria and Imaging-Guided Chemo-Photothermal Therapy.
    Yang GG, Pan ZY, Zhang DY, Cao Q, Ji LN, Mao ZW.
    ACS Appl Mater Interfaces; 2020 Sep 30; 12(39):43444-43455. PubMed ID: 32883070
    [Abstract] [Full Text] [Related]

  • 11. Alternative mechanism of action of the DNP PtIV prodrug: intracellular cisplatin release and the mitochondria-mediated apoptotic pathway.
    Krasnovskaya O, Spector D, Erofeev A, Gorelkin P, Akasov R, Skvortsov D, Trigub A, Vlasova K, Semkina A, Zyk N, Beloglazkina E, Majouga A.
    Dalton Trans; 2021 Jun 15; 50(23):7922-7927. PubMed ID: 34037020
    [Abstract] [Full Text] [Related]

  • 12. Novel SERCA2 inhibitor Diphyllin displays anti-tumor effect in non-small cell lung cancer by promoting endoplasmic reticulum stress and mitochondrial dysfunction.
    Xu Z, Shi Y, Zhu L, Luo J, Hu Q, Jiang S, Xiao M, Jiang X, Wang H, Xu Y, Jin W, Zhou Y, Wang P, Wang K.
    Cancer Lett; 2024 Aug 28; 598():217075. PubMed ID: 38909775
    [Abstract] [Full Text] [Related]

  • 13. Chlorambucil-conjugated platinum(IV) prodrugs to treat triple-negative breast cancer in vitro and in vivo.
    Ma ZY, Wang DB, Song XQ, Wu YG, Chen Q, Zhao CL, Li JY, Cheng SH, Xu JY.
    Eur J Med Chem; 2018 Sep 05; 157():1292-1299. PubMed ID: 30195239
    [Abstract] [Full Text] [Related]

  • 14. Bromocoumarinplatin, targeting simultaneously mitochondria and nuclei with p53 apoptosis pathway to overcome cisplatin resistance.
    Ma J, Li L, Yue K, Li Y, Liu H, Wang PG, Wang C, Wang J, Luo W, Xie S.
    Bioorg Chem; 2020 Jun 05; 99():103768. PubMed ID: 32217375
    [Abstract] [Full Text] [Related]

  • 15. Novel Indole-Chalcone Derivative-Ligated Platinum(IV) Prodrugs Attenuate Cisplatin Resistance in Lung Cancer through ROS/ER Stress and Mitochondrial Dysfunction.
    Liu Z, Wang M, Huang R, Hu T, Jing Y, Huang X, Hu W, Cao G, Wang H.
    J Med Chem; 2023 Apr 13; 66(7):4868-4887. PubMed ID: 36946996
    [Abstract] [Full Text] [Related]

  • 16. A dual-targeting hybrid platinum(IV) prodrug for enhancing efficacy.
    Xiao H, Yan L, Zhang Y, Qi R, Li W, Wang R, Liu S, Huang Y, Li Y, Jing X.
    Chem Commun (Camb); 2012 Nov 11; 48(87):10730-2. PubMed ID: 23012698
    [Abstract] [Full Text] [Related]

  • 17. Platinum(IV) complexes conjugated with phenstatin analogue as inhibitors of microtubule polymerization and reverser of multidrug resistance.
    Huang X, Huang R, Gou S, Wang Z, Liao Z, Wang H.
    Bioorg Med Chem; 2017 Sep 01; 25(17):4686-4700. PubMed ID: 28728896
    [Abstract] [Full Text] [Related]

  • 18. Mitochondria-targeted platinum(II) complexes induce apoptosis-dependent autophagic cell death mediated by ER-stress in A549 cancer cells.
    Wang FY, Tang XM, Wang X, Huang KB, Feng HW, Chen ZF, Liu YN, Liang H.
    Eur J Med Chem; 2018 Jul 15; 155():639-650. PubMed ID: 29935437
    [Abstract] [Full Text] [Related]

  • 19. Reprogramming axial ligands facilitates the self-assembly of a platinum(iv) prodrug: overcoming drug resistance and safer in vivo delivery of cisplatin.
    Fang T, Ye Z, Wu J, Wang H.
    Chem Commun (Camb); 2018 Aug 14; 54(66):9167-9170. PubMed ID: 30062328
    [Abstract] [Full Text] [Related]

  • 20. A Pt(IV) Prodrug Combining Chlorambucil and Cisplatin: a Dual-Acting Weapon for Targeting DNA in Cancer Cells.
    Montagner D, Tolan D, Andriollo E, Gandin V, Marzano C.
    Int J Mol Sci; 2018 Nov 27; 19(12):. PubMed ID: 30486477
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.